Immune characteristics of severe and critical COVID-19 patients

Signal Transduct Target Ther. 2020 Aug 31;5(1):179. doi: 10.1038/s41392-020-00296-3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • B-Lymphocytes / immunology
  • B-Lymphocytes / virology
  • Betacoronavirus / immunology*
  • Betacoronavirus / pathogenicity
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / virology
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / virology
  • COVID-19
  • Case-Control Studies
  • Coronavirus Infections / diagnostic imaging
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / mortality
  • Coronavirus Infections / virology
  • Disease Progression
  • Female
  • Humans
  • Interleukin-10 / blood
  • Interleukin-10 / immunology
  • Interleukin-6 / blood
  • Interleukin-6 / immunology
  • Killer Cells, Natural / immunology
  • Killer Cells, Natural / virology
  • Lung / diagnostic imaging
  • Lung / immunology*
  • Lung / virology
  • Lymphocyte Count
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / diagnostic imaging
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / mortality
  • Pneumonia, Viral / virology
  • Prognosis
  • Proteoglycans
  • SARS-CoV-2
  • Severity of Illness Index
  • Survival Analysis
  • Tomography, X-Ray Computed
  • beta-Glucans / blood
  • beta-Glucans / immunology

Substances

  • IL10 protein, human
  • IL6 protein, human
  • Interleukin-6
  • Proteoglycans
  • beta-Glucans
  • Interleukin-10
  • polysaccharide-K